Business

6 Months Ended

Jun. 30, 2013

Business

1. Business

ARIAD is a global oncology company whose vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.

In December 2012, the Company obtained accelerated approval from the U.S. Food and Drug Administration (“FDA”) to sell its first new cancer medicine, Iclusig^® (ponatinib), and commenced sales and marketing of Iclusig in the United States in January 2013. Accordingly, the Company’s financial statements as of and for the three-month and six-month periods ended June 30, 2013 include product revenue and other transactions related to commercialization that did not exist in prior periods.

On July 2, 2013, the Company announced that the European Commission granted marketing authorization for Iclusig in the European Union, and we have commenced sales efforts in certain European countries.